Trial Profile
A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs NT 501 (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- 15 Nov 2022 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 15 Nov 2022 Planned primary completion date changed from 15 Aug 2023 to 15 Aug 2024.
- 13 Aug 2021 Planned End Date changed from 1 Dec 2021 to 15 Dec 2023.